Vaccine Development Forum link

March 3, 2008

I see that " safety " is not among the top ten concerns of vaccine

development. But shelf life and putting in more aluminum is!

http://www.iirusa.com/vaccines/eventhome/39154.xml

What Are the Top Ten Challenges Cited By Scientists in Vaccines

Development?

-Improving Compliance Through Better Understanding of Regulatory

Requirements

-Formulating More Thermostable Vaccines

-Defining and Implementing a Development Plan Leading To a

Commercially Viable Cancer Vaccine

-Utilizing Forced Degradation and Accelerated Study Practices When

Developing Vaccines

-Improving Stability and Robustness When Developing Influenza

Vaccines

-Taping Into Methods to Advance Vaccine Stability Testing to

Minimize -Development Changes

-***Using Aluminum-Containing Adjuvants Effectively For Improved

Formulation and Stability***

-Identifing and Solving Potential Adjuvant-Antigen Formulation Issues

-Addressing the regulatory issues arising from incorporating a new

adjuvant in your vaccine

-Using Innovative Vaccine Delivery Techniques and Predict Their

Impact on Formulation and Stability Studies

--------------------------------------------------------

Sheri Nakken, former R.N., MA, Hahnemannian Homeopath

Vaccination Information & Choice Network, Nevada City CA & Wales UK

Vaccines - http://www.wellwithin1.com/vaccine.htm Vaccine Dangers &

Childhood Disease & Homeopathy Email classes start in March

March 3, 2008

Here's where I see this becomes more (I'm at a lack of a word) so I'll say

" insane " as it comes to the US schedule, and as more and more vaccinations are

in the pipeline to be introduced as " recommendations " (whereas some " overlook "

recommendations as " requirements " )

I was reading a court decision today which had what the word " effectiveness "

means in terms of vaccinations (or medical counteracts) according to the 21 CFR

(see below):

" Effectiveness means a " reasonable " (quotes by me) expectation that, in a

significant proportion of the target population, the pharmacological or other

effect of the biologic product, when used under adquate directions, for use and

warnings against unsafe use, will serve a clinicially significant function in

the diagnosis, cure, mitigation, treatment, or prevention of disease in man " .

Let us put that aside for a second that " effectiveness " is really based on an

assuption of " reasonable expectations " .

If we are to accept " reasonable expectations " in terms of " effectiveness " ,

then, we must also be able to accept " plausibilities " as it relates to adjuvants

(not just Mercury, but all, in addition to different vaccine components) as

being equally the same as detrimental in terms of AE's.

To promote one while discounting the other, while both remain as

" plausibilties " is not only bad science, it's bad public health policy.

-------------------------------------------------------------